David Rizzieri

10PUBLICATIONS
122CO-AUTHORS
Haematological tumoursMolecular targetsHaematologyCardiovascular medicine and haematology not elsewhere classifiedPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 23, 2024
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.

Naveen Pemmaraju, Yazan F Madanat, David Rizzieri

|Nov 07, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.

Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus

|Nov 18, 2022
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet

|Jun 06, 2022
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.

Kevin H Lin, Justine C Rutter, Abigail Xie

|Oct 20, 2021
Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.

Patrick J Smith, Meagan Lew, Yen Lowder

|Sep 22, 2021
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.

Kamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin

Pageof 2

Frequent Collaborators

3 joint publications

Vijaya Raj Bhatt

3 joint publications

Stephen Strickland

3 joint publications

Mark R Litzow

2 joint publications

Brenda Sandmaier